Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:39 PM
Ignite Modification Date: 2025-12-24 @ 4:39 PM
NCT ID: NCT02616666
Eligibility Criteria: Inclusion Criteria: For inclusion in the study patients should fulfil the following criteria at the time of screening: 1. Provision of informed consent prior to any study specific procedures 2. Females and males aged ≥18 years up to ≤ 75 years 3. Diagnosed with Type 2 Diabetes Mellitus. 4. Uncontrolled on first-line metformin treatment, defined as ≥8 weeks on maximum tolerated dose of metformin and HbA1c \> 6.5%. 5. Ability to read and write as judged by the investigator. Exclusion Criteria: Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) 2. Previous enrolment or randomization in the present study 3. Age \> 75 years 4. Pregnancy/active breast feeding at the time of inclusion 5. Known moderate to severe renal impairment (eGFR\<60ml/min). 6. Participation in an interventional clinical trial ≤ 3 months before enrolment. 7. Unsuitable to participate on mental health grounds, as judged by the investigator. 8. Physician decision to use, as second line treatment, insulin, a GLP1 agonist compound or a SGLT2 inhibitor different from dapagliflozin. 9. Presence of any of the characteristics in which the products in study are contraindicated, as per current labels.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT02616666
Study Brief:
Protocol Section: NCT02616666